

Agenda

8:00 am - 9:00 am	Welcome and Introductions
9:00 am – 9:45 am	Discussion How do Patient Reported Outcomes Support the Mission of Your Organization?
9:45 am – 10:45 am	Panel Discussion Exploring the Developments in Patient Reported Outcomes for Drug Approvals and Quality Measures
10:45 am – 11:00 am	Break
11:00 am – 12:15 pm	Breakout Session (with Report Out) Creating the Future State of Patient Reported Outcomes
12:15 pm – 1:00 pm	Lunch
1:00 pm - 2:00 pm	Panel Discussion Addressing Obstacles that Impact Patient Reported Outcomes Utilization
2:00 pm – 3:00 pm	Breakout Session (with Report Out) Making the Future State a Reality
3:00 pm - 3:30 pm	Discussion AMCP Patient Reported Outcomes Survey
3:30 pm – 3:45 pm	Close Defining Next Steps

Antitrust Guidelines

The Academy follows strict antitrust guidelines. Attendees are to review the following statement:

AMCP's policy is to comply fully and strictly with all federal and state antitrust laws. Meetings held under the auspices of the Academy must be conducted in a manner that avoids the fact or appearance of conduct that may violate the antitrust laws. Participants are not to discuss industry-wide or individual company prices (current or projected) or matters relating to pricing such as cost, profits, contractual terms and conditions (e.g., discounts, credit terms), wages/salaries, market allocation, market shares/sales or clients/customers.

Please see www.amcp.org/antitrust for full statement.

Discussion: How do Patient Reported Outcomes Support the Mission of Your Organization?

Instructions (15 minutes): Using the flipchart, capture how PROs support the mission of each stakeholder at the table

Report Out (30-minutes): Moderator will call on each table to share their findings

Breakout Session: Creating the Future State of Patient Reported Outcomes

Instructions (45 minutes): Using a flipchart please capture the following:

Step 1: Refine the draft priorities for each stakeholder

STAKEHOLDER	PRIORITIES
Patient Advocacy	Active role in health care decisions
	Improve care for themselves and others
Provider	Evaluate treatment effectiveness
	Shared decision making and patient engagement
Payer	Access to products and services
	Appropriate use products and services
Manufacturer	Development of new products services
	Ongoing surveillance of existing products and services

Step 2: Create an ideal future state for PROs to drive patient care

Step 3: Describe how each stakeholder (Patient | Provider | Payer | Manufacturer) engages to operationalize the ideal state

Report Out (30-minutes): Moderator will ask each table to share their findings.

Breakout Session: Making the Future State a Reality

Instructions (30-minutes): Using a flip chart determine what the top 2-3 actions are needed over the next 3 years to support the PRO ideal state

Report Out (30-minutes): Moderator will ask each table to share their findings

Discussion AMCP Patient Reported Outcomes Survey

Instructions (15-minutes): Review the following survey wireframe for patients and stakeholders. Using a flipchart provide any feedback and suggestions regarding survey domains and research methodology

Report Out (15-minutes): Moderator will ask each table to share their findings

Survey Wireframe - Patients

Patients with disease states where outcomes are difficult to clinically measure and patient's perspective necessary to evaluate treatment effectiveness (psoriatic arthritis, psoriasis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease)

ELECTRONIC FORMAT SURVEY DOMAINS
<ul style="list-style-type: none"> What do patients value in treatments? Demographics Clinical History QOL Rate existing PROs level of importance Data utilization: How you want this data to be used? Select from provided categories with write in section

Survey Wireframe - Health Plans | Payers | Providers | Manufacturers | Advocacy | Professional Associations

INTERVIEW FORMAT SURVEY DOMAINS
<ul style="list-style-type: none"> Stakeholder background (e.g. professional history, current position, how many years of experience in specific therapeutic areas of interest, experience using PROs in current role or in the past) Use of PROs at organization; Existing level of PRO importance Views on PROs and utilization more generally (for the field) and data utilization: How do/will you use this data? Challenges to managing the collection of PROs and ensuring they are meaningful for organizational decision-making Recommendations for strengthening organization's PRO data capture and ensuring adherence to methodologic standards How are measures important to patients defined in a manner that leads to adoption by providers and coverage by payers?

Notes Page